Menu Search
Equities

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

T14:SES

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.34
  • Today's Change-0.02 / -0.85%
  • Shares traded17.60k
  • 1 Year change+32.95%
  • Beta0.7884
Data delayed at least 10 minutes, as of Nov 12 2024 08:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast in CNY

The one analyst offering a 12 month price target expects Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd share price to fall to 1.22 in the next year from the last price of 2.34.
High-47.8%1.22
Med-47.8%1.22
Low-47.8%1.22

Dividends

In 2023, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd reported a dividend of 1.15 CNY, which represents a 16.51% increase over last year. The analyst covering the company expects dividends of 1.28 CNY for the upcoming fiscal year, an increase of 11.14%.
Div growth (TTM)16.51%
More ▼

Earnings history & estimates in CNY

Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd reported annual 2023 earnings of 1.28 per share on Mar 29, 2024.
Average growth rate+15.18%
More ▼

Revenue history & estimates in CNY

Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd had revenues for the full year 2023 of 8.22bn. This was 0.33% below the prior year's results.
Average growth rate+9.87%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.